期刊
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
卷 53, 期 3, 页码 341-345出版社
WILEY
DOI: 10.1002/ccd.1178
关键词
dopamine agonist; acute renal failure; contrast; kidney; angiography
We evaluated the ability of fenoldopam, a newly available renal vasodilator, to prevent radiocontrast nephropathy in high-risk patients undergoing interventional diagnostic and therapeutic angiographic procedures. We reviewed the results from 46 consecutive procedures in patients with serum creatinine, 1.5 mg/dL if diabetic and > 1.7 mg/dL if nondiabetic. We compared our results to a previously published cohort of similarly at-risk patients. The incidence of radiocontrast nephropathy, defined as an increase in serum creatinine of greater than or equal to 25% at 48 hr following the procedure, was 13% in the group treated with fenoldopam, compared to an expected 38%, The percentage change in serum creatinine at 48 hr was +16% vs. +118%, respectively, in the two groups. In this preliminary experience, the use of fenoldopam in high-risk patients appears to minimize the likelihood of radioncontrast nephropathy. (C) 2001 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据